Halozyme (HALO) Director Dannielle Appelhans Receives Awards

What Happened
Dannielle Appelhans, a director of Halozyme Therapeutics, was granted equity awards on 2026-09-01: 1,161 restricted stock units (RSUs) and 1,778 option-style units (reported as a derivative grant). Both awards were reported at a per-share price of $0.00 (grant), so no cash was exchanged at grant.

Key Details

• Transaction date: 2026-09-01; Form 4 filed 2026-09-02 (timely filing).
• Grants: 1,161 RSUs (footnote F1) and 1,778 derivative option units (footnote F2); both shown at $0.00 per share, total reported value $0.
• Vesting: RSUs vest on the issuer’s 2027 annual meeting of stockholders (F1). The option grant vests in full on the issuer’s 2027 annual meeting (F2).
• Shares owned after transaction: Not specified in the provided filing.
• Transaction code: A = Award/Grant. No sale, purchase, or exercise occurred in this filing.

Context
These are standard director compensation grants (RSUs and option-style awards) and do not reflect an open-market buy or sale. Vesting is scheduled at the company’s 2027 annual meeting, so the awards are subject to future vesting conditions and are not immediately tradable.